Allegro Biotech

About:

Game-changing therapeutic nanoparticles for neuroscience, chronic degenerative diseases and orthopaedics.

Website: https://allegro.bio/

Top Investors: Meusinvest (Noshaq), KBC, Annie Vereecken

Description:

Allegro was founded in 2021 with the ultimate vision to augment humanity and prolong life, engineering the body atom-by-atom, blending nanotech and biotech. The company developed a promising nanotechnology platform to build therapeutic nanoparticles for orthopaedics, neuroscience, and chronic degenerative diseases. Allegro brings Xyletra to the market, the world's first disease-modifying treatment for osteoarthritis, which stops the degenerative process and alleviates pain with a year-long effect on a single shot administration.

Total Funding Amount:

7M EUR

Headquarters Location:

Liège, Liege, Belgium

Founded Date:

2021-04-21

Contact Email:

info(AT)allegro.bio

Founders:

Jorg Schelfhout, Lucas Decuypere

Number of Employees:

11-50

Last Funding Date:

2023-04-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai